← Back to Search


Monitoring Atrial Fibrillation After COVID-19 (unCOVer-AF Trial)

Waitlist Available
Led By Andrea Natale, MD
Research Sponsored by Texas Cardiac Arrhythmia Research Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a first clinical episode of AF ≥30 s at admission or during hospitalization for COVID-19
Patients with implantation of an ILR, a PMK, or an ICD during COVID-19 hospitalization or within 30 days after hospital discharge, or an ILR, a PMK, or an ICD implanted before COVID-19 hospitalization
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

unCOVer-AF Trial Summary

This trial is looking at the natural history of atrial fibrillation (AF) in patients who have had their first arrhythmic episode during COVID-19 hospitalization.

Who is the study for?
This trial is for adults over 18 who had their first episode of atrial fibrillation during COVID-19 hospitalization. They must have a confirmed SARS-CoV-2 infection and either already have or get an ILR, PMK, or ICD device implanted. People with a history of AF, severe heart valve issues, kidney failure on dialysis, or conditions that could risk their safety can't join.Check my eligibility
What is being tested?
The study is tracking the progression of atrial fibrillation in patients who experienced it for the first time while hospitalized with COVID-19. It uses devices like ILRs (implantable loop recorders), PMKs (pacemakers), and ICDs (implantable cardioverter-defibrillators) to monitor heart rhythm continuously.See study design
What are the potential side effects?
While this study focuses on observation rather than treatment, implanting devices like ILRs, PMKs, and ICDs can cause risks such as infection at the site of implantation, bleeding, pain at the implant site, and potential malfunction of the device.

unCOVer-AF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
You have a certain heart condition called atrial fibrillation that lasts for more than 30 seconds.
You have had a heart device implanted during or shortly after being hospitalized for COVID-19, or before being hospitalized for COVID-19.

unCOVer-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AF Burden
AF Progression
Time to adjudicated ischemic stroke/transient ischemic attack (TIA)/systemic arterial embolism
Secondary outcome measures
Composite of all-cause mortality, stroke and bleeding
Time to adjudicated cardiovascular death

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

unCOVer-AF Trial Design

1Treatment groups
Experimental Treatment
Group I: COVID-19 patients with new-onset AFExperimental Treatment1 Intervention
Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.

Find a Location

Who is running the clinical trial?

Texas Cardiac Arrhythmia Research FoundationLead Sponsor
37 Previous Clinical Trials
13,180 Total Patients Enrolled
26 Trials studying Atrial Fibrillation
6,445 Patients Enrolled for Atrial Fibrillation
Domenico G Della Rocca, MDStudy DirectorTexas Cardiac Arrhythmia Research Foundation
Andrea Natale, MDPrincipal InvestigatorTexas Cardiac Arrhythmia Research Foundation
35 Previous Clinical Trials
8,018 Total Patients Enrolled
26 Trials studying Atrial Fibrillation
7,239 Patients Enrolled for Atrial Fibrillation

Media Library

ICD (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04830774 — N/A
Atrial Fibrillation Research Study Groups: COVID-19 patients with new-onset AF
Atrial Fibrillation Clinical Trial 2023: ICD Highlights & Side Effects. Trial Name: NCT04830774 — N/A
ICD (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04830774 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any more opportunities for enrollment in the trial?

"Affirmative. The information on clinicaltrials.gov confirms that this medical investigation, which was initially launched on April 15th 2021, is actively recruiting participants. Around 200 people must be enrolled from 3 distinct research centres."

Answered by AI

How many participants are actively enrolled in this research endeavor?

"To successfully conduct the trial, 200 qualified subjects are required. Participants can come from two different locations - Texas Cardiac Arrhythmia Institute in Austin or Kansas City Heart Rhythm Institute in Overland Park."

Answered by AI
~52 spots leftby Feb 2025